Engineered Exosomes for NK Cell Expansion Without Live Feeders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hematopoietic stem cell transplantation methods face challenges such as the lack of matched donors, increased incidence of graft-versus-host disease, graft failure, and high relapse rates due to residual cancer cells, limiting their effectiveness and applicability, especially for patients without a matched sibling donor.
Innovation Solution
The use of NK-stimulating exosomes comprising peptides like 4-1BBL and IL-21, produced by engineered cell lines, to enhance NK cell activity and expansion, allowing for allogeneic or haploidentical transplant procedures without causing graft-versus-host disease, and potentially combining with bioreactors for ex vivo expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If allogeneic stem cell transplant is performed without matched donor, then treatment can proceed for more patients, but graft-versus-host disease incidence increases
Solution Approach 1:
The patent uses engineered feeder cells as intermediaries that secrete exosomes containing stimulatory peptides (4-1BBL, IL-21, IL-15) to mediate NK cell expansion. These exosomes act as mediators that provide the necessary stimulation without requiring direct contact between NK cells and feeder cells, thereby reducing alloreactivity and graft-versus-host disease while maintaining NK cell proliferation and activation.
Solution Approach 2:
The patent extracts and isolates exosomes containing stimulatory peptides from engineered feeder cells. By separating the beneficial stimulatory components (exosomes with 4-1BBL, IL-21, IL-15) from the potential harmful alloreactive components (live feeder cells), the invention enables NK cell expansion without the risk of graft-versus-host disease caused by residual feeder cell contamination.
2Quantity of substance
If traditional NK cell expansion methods using live feeder cells are used, then NK cell proliferation is achieved, but treatment complexity and facility requirements increase
Solution Approach 1:
The patent creates a simplified version of the complex feeder cell system by producing exosomes that copy and transmit the essential stimulatory signals (4-1BBL, IL-21, IL-15) without requiring the entire live cell infrastructure. These exosome copies can be produced in advance, stored, and administered without needing specialized cell culture facilities during patient treatment.
Solution Approach 2:
The patent segments the NK cell expansion process into distinct phases: (1) production of exosomes from engineered feeder cells in a controlled setting, (2) isolation and characterization of exosomes, and (3) administration to patients. This segmentation allows the complex feeder cell work to be done once during exosome production, while patient treatment uses only the simplified exosome product.
3Reliability
If donor lymphocyte infusion is used to treat relapse, then some cancer control is achieved, but T cell mediated graft-versus-host disease worsens outcomes
Solution Approach 1:
The patent applies local quality by selectively stimulating NK cells with specific peptides (4-1BBL, IL-21, IL-15) that are localized to exosome surfaces. This targeted stimulation enhances NK cell function and cancer control while avoiding the generalized T cell activation that causes graft-versus-host disease in traditional donor lymphocyte infusion.
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
Disclosed herein are novel compositions and methods for stimulation of and the production or expansion of natural killer (NK) cells. Numbers of NK cells can be increased following contact with exosomes modified with one or more stimulatory peptides. Methods and compositions for the production of exosomes, wherein the exosomes comprises stimulatory peptides are also described. Also described are methods of treating cancer using the disclosed NK-stimulating exosomes or NK cells stimulated by the disclosed methods.